This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): nesiritide
Description: Natrecor is a recombinant form of human B-type natriuretic peptide, or BNP, a naturally occurring hormone in the body that aids in the healthy functioning of the heart. BNP is released in response to ventricular stretch, and will cause vasorelaxation, inhibition of aldosterone secretion in the adrenal cortex, and inhibition of renin secretion in the kidney. BNP causes natriuresis (excretion of sodium in the urine) and a reduction in intravascular volume. The natriuretic effect results from a direct inhibition of sodium absorption in the renal collecting duct, increased glomerular infiltration (filtering of the blood to form urine) and inhibited aldosterone production and secretion.
Deal Structure: In January 2001, Scios entered into a marketing alliance with Innovex, a division of Quintiles, to commercialize Natrecor in North America. Innovex agreed to deliver sales and marketing solutions to Scios. In December 2001, Scios amended the January 2001 agreement in relation to the Natrecor sales force and the infrastructure supporting it. The amendment stated that Scios agreed to, at their option, assume control of the Natrecor sales force in June 2003. Under the amended agreement, PharmaBio, a corporate venture group related to Quintiles, agreed to still provide the $30.0 million in funding to commercialize Natrecor, however the $5.0 million line of credit was eliminated.
Partners: Pharma Services Holding, Inc.
Pink Sheet Pharma Deals With The DOJ
Additional information available to subscribers only: